Pharmacokinetics of the taxanes

Pharmacotherapy

Volumn 17, Issue 5 II SUPPL., 1997, Pages

  Kearns, Christine M ^a,b,c  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^c Foti and Lazo Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; CANCER; CONFERENCE PAPER; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; HUMAN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; HUMANS; PACLITAXEL; TAXOIDS;

EID: 0030765910     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (23)

1. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-14.
2. Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995;13:2643-55.
3. Cresteil T, Monsarrat PA, Alvinerie P, Treluyer JM, Vieira I, Wright M. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994;54:386-92.
4. Harris JW, Rahman A, Kim BR, Guengerich P, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994;15:4026-35.
5. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54: 5543-6.
6. Marre F, Sanderink GJ, de Sousa G, et al. Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996;56: 1296-1302.
7. Royer I, Monsarrat B, Sonnier M, Wright M, Cresteil T. Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs. Cancer Res 1996;56:58-65.
8. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
9. Sonnichsen DS, Hurwitz CA, Pratt CB, Shuster JJ, Relling MV. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors. J Clin Oncol 1994;12:532-8.
10. Kearns CM, Gianni L, Egorin MJ. Paclitaxel pharmacokinetics and pharmacodynamics. Semin Oncol 1995;22(suppl 6):16-23.
11. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M. Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 1993;53:1037-42.
12. Launay-Iliadis MC, Bruno R, Cosson V, et al. Population pharmacokinetics of docetaxel during phase 1 studies using nonlinear mixed-effect modeling and nonparametric maximum-likelihood estimation. Cancer Chemother Pharmacol 1995;37:47-54.
13. Guéritte-Voegelein F, Guénard D, Lavelle F, LeGoff M-T, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991;34:992-8.
14. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993;19:351-86.
15. Ohtsu T, Sasaki Y, Tamura T, et al. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1995;1:599-606.
16. Kearns C, Gianni L, Vigano L, et al. Nonlinear pharmacokinetics of paclitaxel in humans [abstr]. Proc Am Soc Clin Oncol 1993;12:135.
17. Hryniuk WM. Average relative dose intensity and the impact on design of clinical trials. Semin Oncol 1987;14:65-74.
18. Frei E, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
19. Woodcock DM, Jefferson S, Linsenmeyer ME, et al. Reversal of the multidrug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res 1990;50:4199-203.
20. Ross DD, Wooten PJ, Tong Y, et al. Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia cells by cyclosporin A and Cremophor EL. Blood 1994;83:1337-47.
21. Horwitz SB, Lothstein L, Manfredi JJ, et al. Taxol: mechanisms of action and resistance. Ann NY Acad Sci 1986;466:733-44.
22. Webster L, Linsenmeyer M, Millward M, Morton C, Bishop J, Woodcock D. Measurement of Cremophor EL following taxol: plasma levels sufficient to reverse exclusion mediated by the multidrug-resistant phenotype. J Natl Cancer Inst 1993;85:1685-90.
23. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res 1996;56:2112-15.